Motor complications, levodopa metabolism and progression of Parkinson's disease

Bibliography

• Riederer P, Gerlach M, Muller T, Reichmann H. Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. Parkinsonism Relat Disord 2007;13:466-79
   PubMed Web of Science ®Google Scholar
• Fujita Y, Izawa Y, Ali N, Pramipexole protects against H2O2-induced PC12 cell death. Naunyn Schmiedebergs Arch Pharmacol 2006;372:257-66
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-91
   PubMed Web of Science ®Google Scholar
• Muller T. The impact of COMT-inhibition on gastrointestinal levodopa absorption in patients with Parkinson's disease. Clin Med Insights Ther 2010;2:155-68
   Google Scholar
• Kurlan R, Rothfield KP, Woodward WR, Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobility. Neurology 1988;38:419-21
   PubMed Web of Science ®Google Scholar
• Nyholm D, Nilsson Remahl AI, Dizdar N, Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-23
   PubMed Web of Science ®Google Scholar
• Melamed E, Hefti F, Wurtman RJ. Nonaminergic striatal neurons convert exogenous l-dopa to dopamine in parkinsonism. Ann Neurol 1980;8:558-63
   PubMed Web of Science ®Google Scholar
• Ekesbo A, Rydin E, Torstenson R, Dopamine autoreceptor function is lost in advanced Parkinson's disease. Neurology 1999;52:120-5
   PubMed Web of Science ®Google Scholar
• Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 2000;55(11 Suppl 4), S72-7
   PubMed Web of Science ®Google Scholar
• Cenci MA, Konradi C. Maladaptive striatal plasticity in l-DOPA-induced dyskinesia. Prog Brain Res 2010;183:209-33
   PubMed Web of Science ®Google Scholar
• Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 2008;9:665-77
   PubMed Web of Science ®Google Scholar
• Muller T. Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-l-methionine and related mechanisms. Int Rev Neurobiol 2010;95:49-71
   PubMed Web of Science ®Google Scholar
• Muller T. Role of homocysteine in the treatment of Parkinson's disease. Expert Rev Neurother 2008;8:957-67
   PubMedGoogle Scholar
• Cacciapuoti F. Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties. J Thromb Thrombolysis 2011: published online 14 January 2011, doi: 10.1007/s11239-011-0550-4
   PubMed Web of Science ®Google Scholar
• Castro R, Rivera I, Martins C, Intracellular S-adenosylhomocysteine increased levels are associated with DNA hypomethylation in HUVEC. J Mol Med 2005;83:831-6
   PubMed Web of Science ®Google Scholar
• Fuso A, Seminara L, Cavallaro RA, S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 2005;28:195-204
   PubMed Web of Science ®Google Scholar
• James SJ, Melnyk S, Pogribna M, Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr 2002;132(8 Suppl):2361S-6S
   PubMed Web of Science ®Google Scholar
• Tanner CM, Ross GW, Jewell SA, Occupation and risk of Parkinsonism: a multicenter case-control study. Arch Neurol 2009;66:1106-13
   PubMed Web of Science ®Google Scholar
• Isobe C, Murata T, Sato C, Terayama Y. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. Life Sci 2005;77:1836-43
   PubMed Web of Science ®Google Scholar
• Muller T, Renger K, Kuhn W. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 2004;61:657-60
   PubMed Web of Science ®Google Scholar
• Manca D, Cossu G, Murgia D, Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy. Mov Disord 2009;24:2293-4
   PubMed Web of Science ®Google Scholar
• Onofrj M, Bonanni L, Cossu G, Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment. Parkinsonism Relat Disord 2009;15( Suppl 3):S233-6
   PubMed Web of Science ®Google Scholar
• Muller T, Jugel C, Ehret R, Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal Levodopa/Carbidopa gel. J Neural Transm 2011; published online 27 February 2011, DOI 10.1007/s00702-011-0614-9
   Web of Science ®Google Scholar
• Muhlack S, Woitalla D, Welnic J, Chronic levodopa intake increases levodopa plasma bioavailability in patients with Parkinson's disease. Neurosci Lett 2004;363:284-7
   PubMed Web of Science ®Google Scholar
• Woitalla D, Goetze O, Kim JI, Levodopa availability improves with progression of Parkinson's disease. J Neurol 2006;253:1221-6
   PubMed Web of Science ®Google Scholar
• Muller T, Woitalla D, Saft C, Kuhn W. Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism Relat Disord 2000;6:171-3
   PubMed Web of Science ®Google Scholar
• Zappia M, Crescibene L, Arabia G, Body weight influences pharmacokinetics of levodopa in Parkinson's disease. Clin Neuropharmacol 2002;25:79-82
   PubMed Web of Science ®Google Scholar
• Bachmann CG, Zapf A, Brunner E, Trenkwalder C. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias. Eur J Neurol 2009;16:895-901
   PubMed Web of Science ®Google Scholar
• Hassin-Baer S, Cohen O, Vakil E, Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications. Clin Neuropharmacol 2006;29(6):305-111
   PubMed Web of Science ®Google Scholar
• O'Suilleabhain PE, Sung V, Hernandez C, Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004;61:865-8
   PubMed Web of Science ®Google Scholar
• O'Suilleabhain PE, Oberle R, Bartis C, Clinical course in Parkinson's disease with elevated homocysteine. Parkinsonism Relat Disord 2006;12:103-7
   PubMed Web of Science ®Google Scholar
• Nissinen E, Nissinen H, Larjonmaa H, The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats. J Neural Transm 2005;112:1213-21
   PubMed Web of Science ®Google Scholar
• Henninger N, Wang Q, Okun JG, Nitrous oxide promotes hyperhomocysteinemia in levodopa treated rats. Parkinsonism Relat Disord 2007;13:524-7
   PubMed Web of Science ®Google Scholar
• Muller T, Kuhn W. Homocysteine levels after acute levodopa intake in patients with Parkinson's disease. Mov Disord 2009;24:1339-43
   PubMed Web of Science ®Google Scholar
• Muller T, Muhlack S. Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease. Parkinsonism Relat Disord 2010;16:688-9
   PubMed Web of Science ®Google Scholar
• Ben Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 1995;58:293-9
   PubMed Web of Science ®Google Scholar
• Gorell JM, Johnson CC, Rybicki BA. Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology 1994;44:1865-8
   PubMed Web of Science ®Google Scholar
• Nakaso K, Yasui K, Kowa H, Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with l-DOPA, homocysteine, and MTHFR genotype. J Neurol Sci 2003;207(1-2):19-23
   PubMed Web of Science ®Google Scholar
• Song C, Kanthasamy A, Anantharam V, Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration. Mol Pharmacol 2010;77:621-32
   PubMed Web of Science ®Google Scholar
• Zeevalk GD, Razmpour R, Bernard LP. Glutathione and Parkinson's disease: is this the elephant in the room? Biomed Pharmacother 2008;62:236-49
   PubMed Web of Science ®Google Scholar
• Zhang CE, Tian Q, Wei W, Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiol Aging 2008;29:1654-65
   PubMed Web of Science ®Google Scholar
• Holmgren A, Johansson C, Berndt C, Thiol redox control via thioredoxin and glutaredoxin systems. Biochem Soc Trans 2005;33:1375-7
   PubMed Web of Science ®Google Scholar
• Lyras L, Zeng BY, McKenzie G, Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. J Neural Transm 2002;109:53-67
   PubMed Web of Science ®Google Scholar
• Muller T, Muhlack S. Cysteinyl-glycine reduction as marker for Levodopa induced oxidative stress in Parkinson's disease patients. Mov Disord 2011;26(3):543-6
   PubMed Web of Science ®Google Scholar
• Asanuma M, Miyazaki I, az-Corrales FJ, Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation. Neurosci Res 2008;60:106-13
   PubMed Web of Science ®Google Scholar
• Bao L, Avshalumov MV, Patel JC, Mitochondria are the source of hydrogen peroxide for dynamic brain-cell signaling. J Neurosci 2009;29:9002-10
   PubMed Web of Science ®Google Scholar
• Calabresi P, Di FM, Ghiglieri V, Picconi B. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord 2008;23(Suppl 3), S570-9
   PubMed Web of Science ®Google Scholar
• Shi Q, Savage JE, Hufeisen SJ, l-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists. J Pharmacol Exp Ther 2003;305:131-42
   PubMed Web of Science ®Google Scholar
• Lin JJ, Yueh KY. Plasma homocysteine levels increased risk of levodopa induced dyskinesia in Parkinson's disease. Mov Disord 2010;25 Suppl. 3, S674
   Google Scholar
• Zoccolella S, Lamberti P, Iliceto G, Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias. Clin Chem Lab Med 2006;44:863-6
   PubMed Web of Science ®Google Scholar
• Verhagen Metman L, Del Dotto P, van den Munckhof P, Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-6
   PubMed Web of Science ®Google Scholar
• Ouattara B, Gregoire L, Morissette M, Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol Aging 2009; published online 29 December 2009, doi:10.1016/j.neurobiolaging.2009.07.014
   PubMed Web of Science ®Google Scholar
• Berg D, Hochstrasser H, Schweitzer KJ, Riess O. Disturbance of iron metabolism in Parkinson's disease – ultrasonography as a biomarker. Neurotox Res 2006;9:1-13
   PubMed Web of Science ®Google Scholar
• Bostantjopoulou S, Katsarou Z, Frangia T, Endothelial function markers in parkinsonian patients with hyperhomocysteinemia. J Clin Neurosci 2005;12:669-72
   PubMed Web of Science ®Google Scholar
• Heider I, Lehmensiek V, Lenk T, Dopaminergic neurotoxicity of homocysteine and its derivatives in primary mesencephalic cultures. J Neural Transm Suppl 2004;(68):1-13
   PubMed Web of Science ®Google Scholar
• Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study. Mov Disord 2009;24:1437-44
   PubMed Web of Science ®Google Scholar
• Imamura K, Takeshima T, Nakaso K, Nakashima K. Homocysteine is toxic for dopaminergic neurons in primary mesencephalic culture. Neuroreport 2007;18:1319-22
   PubMed Web of Science ®Google Scholar
• Lee ES, Chen H, Soliman KF, Charlton CG. Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology 2005;26:361-71
   PubMed Web of Science ®Google Scholar
• Ozer F, Meral H, Hanoglu L, Plasma homocysteine levels in patients treated with levodopa: motor and cognitive associations. Neurol Res 2006;28:853-8
   PubMed Web of Science ®Google Scholar
• Rogers JD, Sanchez-Saffon A, Frol AB, az-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003;60:59-64
   PubMed Web of Science ®Google Scholar
• Toth C, Brown MS, Furtado S, Neuropathy as a potential complication of levodopa use in Parkinson's disease. Mov Disord 2008;23:1850-9
   PubMed Web of Science ®Google Scholar
• Zoccolella S, Lamberti P, Iliceto G, Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions. Clin Chem Lab Med 2005;43:1107-10
   PubMed Web of Science ®Google Scholar